Johnson & Johnson Agrees to $5.5 Billion Talc Cancer Settlement

In a significant move to resolve a longstanding legal dispute, pharmaceutical giant Johnson & Johnson has agreed to pay an estimated $5.5 billion to settle tens of thousands of lawsuits alleging that its baby powder and talc products caused ovarian cancer. The landmark deal, announced on Monday, is set to cover approximately 76,000 claims, including those consolidated in a federal court in New Jersey and related cases in state court.

The settlement represents a major development in a decade-long legal battle that has seen numerous plaintiffs file lawsuits against Johnson & Johnson, claiming that its talc products contained asbestos, a known carcinogen linked to ovarian cancer. The company has consistently maintained that its talc products are safe and asbestos-free, but numerous studies have raised concerns about the potential health risks associated with long-term use. The settlement will see Johnson & Johnson resolve nearly all of the remaining talc claims against the company, bringing an end to a contentious and high-stakes legal battle.

The terms of the settlement are expected to bring closure to thousands of plaintiffs who have been affected by the alleged health risks associated with Johnson & Johnson's talc products. While the exact details of the agreement are yet to be disclosed, the estimated $5.5 billion payout is a significant acknowledgment of the severity of the issue and the company's commitment to resolving the matter.